Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Dominantly Inherited Alzheimer Net, Nelly Joseph-Mathurin, Jorge J. Llibre-Guerra, Yan Li, Austin A. McCullough, Carsten Hofmann, Jakub Wojtowicz, Ethan Park, Guoqiao Wang, Gregory M. Preboske, Qing Wang, Brian A. Gordon, Charles D. Chen, Shaney Flores, Neelum T. Aggarwal, Sarah B. Berman, Thomas D. Bird, Sandra E. Black, Bret Borowski, William S. BrooksJasmeer P. Chhatwal, Roger Clarnette, Carlos Cruchaga, Anne M. Fagan, Martin Farlow, Nick C. Fox, Serge Gauthier, Jason Hassenstab, Diana A. Hobbs, Karen C. Holdridge, Lawrence S. Honig, Russ C. Hornbeck, Ging-Yuek R. Hsiung, Clifford R. Jack, Ivonne Z. Jimenez-Velazquez, Mathias Jucker, Gregory Klein, Johannes Levin, Michele Mancini, Mario Masellis, Nicole S. McKay, Catherine J. Mummery, John M. Ringman, Hiroyuki Shimada, B. Joy Snider, Kazushi Suzuki, David Wallon, Chengjie Xiong, Roy Yaari, Eric McDade, Richard J. Perrin, Randall J. Bateman, Stephen P. Salloway, Tammie L. S. Benzinger, David B. Clifford
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease'. Together they form a unique fingerprint.